Cardiac Rhythm Management Devices Market – By Product, By Application, By End Use – Global Forecast, 2025 to 2034

Cardiac Rhythm Management Devices Market Size

The global cardiac rhythm management devices market was valued at USD 23.5 billion in 2024 and is expected to exhibit growth at a CAGR of 5.2% from 2025 to 2034. The market is estimated to grow from USD 25.3 billion in 2025 to USD 39.7 billion by 2034. The growing prevalence of heart failure and other cardiac disorders, the increasing geriatric population, and advancements in product technology are some of the prime variables driving the market growth.
 

As the population of the world grows older, arrhythmias, heart failure, and other cardiovascular diseases are becoming more common. Associated factors include an increase in the population's average age, changes in lifestyle, and the prevalence of comorbidities such as hypertension, diabetes, and obesity. Cardiac abnormalities are primary contributors to the soaring of cardiovascular diseases (CVD), considering that they are the reason behind almost 17.9 million deaths per year according to the cardiac disorders undertaken by World Health Organization (WHO).
 

Low CRM utilization delays effective treatment and worsens the patient's condition, preventing improvement in quality of life. With the rise in these diseases, there is a sudden spike in the market for CRM devices that assist in monitoring, regulating, and treating abnormal heart rhythms.
 

Additionally, the elderly population has a greater risk of suffering from heart failure and other cardiac disorders, which helps explain why there is an increase in the average age of the world's population. This shift in demographics has, in turn, resulted in higher demand for other CRM devices such as defibrillators and pacemakers. The increased reliance of healthcare professionals on CRM devices to manage patients' long-term cardiovascular health enables providers to shift from the treatment of incurable diseases to the preventive and therapeutic care of cardiovascular diseases.
 

Cardiac rhythm management devices are unique medical tools used to keep an eye on and manage the heart's electrical activity, ensuring it beats properly. They help treat different heart rhythm issues and can be placed in patients either temporarily or for the long haul. These devices work to steady any irregular heartbeats, boosting the heart's performance and enhancing the overall quality of life for patients.
 

Cardiac Rhythm Management Devices Market Trends

Technological changes, wireless transmission, including remote supervision miniaturization, and improvement in battery life have made CRM devices more accurate, convenient, and reliable. Such improvements are on the rise within hospitals, clinics, and even homes since they enable more efficient management and monitoring of patients with cardiac conditions.
 

• These advancements extend to the downsizing of CRM systems to less invasive forms such as subcutaneous defibrillators and leadless pacemakers. Not only are these devices more patient-friendly, but they also ease the implantation procedure and minimize the infection risk associated with larger, more conventional implants. The increased availability of miniaturized CRM devices adds to the pool of patients willing to accept heart rhythm management, including the more hesitant individuals undergoing invasive procedures, thus widening the market.
   
• Moreover, improved battery life has significantly increased the reliability of CRM devices, making them easier to trust and less frequently needing replacement. This is particularly beneficial for pacemakers and defibrillators, as patients can go longer periods without undergoing another procedure. Enhanced battery life and robust device construction reduce the chances of complications from frequent device replacements, encouraging both patients and clinicians to use CRM devices.
   
• This shift in demographics has, in turn, resulted in higher demand for other CRM devices such as defibrillators and pacemakers. The increased reliance of healthcare professionals on CRM devices to manage patients' long-term cardiovascular health enables providers to shift from the treatment of incurable diseases to the preventive and therapeutic care of cardiovascular diseases.
   

Cardiac Rhythm Management Devices Market Analysis

Based on product, the market is classified into pacemakers, defibrillators, and cardiac resynchronization therapy devices. The defibrillators segment generated the highest revenue of USD 13.6 billion in 2024. Also, the global market was valued at USD 21.9 billion in 2023.
 

• Defibrillators such as implantable cardioverter defibrillators (ICDs) and external ones are vital for patients who have a high likelihood of experiencing cardiac flashes since they provide electric shocks at the appropriate moments to restore normalcy to the heart's functionalities. With the world continuing to battle against heart disease as one of the primary causes of death, it has transformed the need for effective preventive measures or emergency response tools such as defibrillators.
   
• As more and more people are needing long-term care due to arrhythmias, the use of ICDs has grown significantly, as these devices are able to monitor heart rhythms and deliver corrective shocks at the appropriate time. Most cardiologists and other healthcare professionals prefer ICDs as they can avert fatal outcomes, especially among patients with very complicated heart diseases. Their effectiveness in reducing incidences of sudden cardiac deaths has reinforced their acceptance as the first crude treatment option in CRM systems and has strengthened this segment's market share.
   

Based on application, the cardiac rhythm management devices market is classified into congestive heart failure, arrhythmias, bradycardia, tachycardia, and other applications. The congestive heart failure segment held a dominant market share in 2024 and was valued at over USD 8.6 billion.
 

• ICDs and cardiac resynchronization therapy (CRT) devices have proven highly effective in the treatment of congestive heart failure (CHF) by controlling heart rate, enhancing blood circulation, and minimizing heart workload. For heart failure patients, CRT devices are necessary because they coordinate the contractions of the heart. The use of these devices reduces symptoms of CHF, and further complications, and improves the quality of life of patients. Thus, these devices are considered essential tools in the management of heart failure.
   
• Moreover, the development of new features in CRM devices has greatly improved the management of CHF by introducing real-time monitoring, wireless communication, and remote management of the patient. Remote monitoring enables continuous assessment of patients' heart conditions and device functionality, which decreases the necessity for frequent visits to the office and allows healthcare providers to respond to problems in a timely manner. These improvements have enhanced the treatment of CHF using CRM devices and further confirmed the leadership of this segment.
   

Based on end use, the cardiac rhythm management devices market is segmented into hospitals, cardiac care centers, ambulatory surgical centers, diagnostic centers, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 18.9 billion by the end of the forecast period.
 

• The growing range of hospital-grade cardiac rhythm management devices is expected to boost sales in the relevant hospital departments. This phenomenon is driven by an increase in hospital admissions for cardiac cases, greater screening program coverage, and the availability of certified specialists as doctors.
   
• In developed countries with advanced infrastructure, the rising incidence of cardiovascular diseases is likely to accelerate diagnosis and treatment in healthcare facilities, further driving expansion. Along with the growing occurrence of cardiovascular diseases, this is anticipated to result in an increase in patients visiting the hospital, which in turn, will help grow sales in the hospital segment of cardiac rhythm management devices.
   

The U.S. cardiac rhythm management devices market accounted for USD 11.1 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 4.3% between the 2025 to 2034 period.
 

• The country has a healthcare system in place that is well developed, and there is broad coverage for diagnostic and treatment services, including specialized cardiac units using advanced CRM technology for arrhythmia and heart failure management.
   
• In addition, favorable reimbursement and extensive clinical trials alongside extensive investments into R&D further aid in the adoption of CRM devices, assuring the region's primary rank in terms of market size and innovation will not change.
   

In the Europe cardiac rhythm management devices market, France is projected to grow remarkably in the coming years.
 

• The French government backs cardiac health initiatives that help offer lifesaving devices such as implantable defibrillators and pacemakers.
   
• Furthermore, France has some of the top cardiology research centers in the EU and participates in supranational healthcare collaborations that enhance CRM device development.
   
• Combined with elevated overall concern about cardiovascular health, France's situation makes it an important CRM market in Europe.
   

In the Asia cardiac rhythm management devices market, Japan is projected to grow remarkably in the coming years.
 

• The adoption of CRM devices for the eleventh Japan is a technologically advanced healthcare sector and proactive health management from its citizens.
   
• Furthermore, Japan’s attention to remote patient monitoring is in line with trends in CRM devices, thus expanding this segment of the market.
   
• The Japanese government also supports the development of innovative devices and subsidizes CRM and other advanced technologies, which enhances Japan's standing in the international arena.
   

Cardiac Rhythm Management Devices Market Share

The top five companies hold a 25% market share in the market. These leaders include Medtronic, Abbott, Boston Scientific, Biotronik, and MicroPort CRM. The CRM devices market is growing due to the participation of various international and national players. Several factors contribute to market share changes, such as technological innovations, the granting of new patents, industry mergers and acquisitions, and the development of more efficient and minimally invasive devices. Established firms dominate this market by focusing on technological advancements and product quality.
 

The competitive environment is driven by the interaction between established companies and emerging biotech startups, making both product and price competitiveness crucial. Additionally, the adoption of CRM devices is supported by collaborations between medical device manufacturers and healthcare institutions, further enhancing marketing efforts. The rising demand, fuelled by the increasing prevalence of cardiovascular diseases and the aging population, continues to drive market growth. The market also sees frequent mergers, geographical expansion, and the continuous development of new product versions.
 

Cardiac Rhythm Management Devices Market Companies

Prominent players operating in the cardiac rhythm management devices industry include:

• Abbott
• ABIOMED
• AMIITALIA
• Asahi KASEI
• BIOTRONIK
• Boston Scientific
• BPL Medical Technologies
• CU Medical
• defibtech
• LivaNova
• MEDICO
• Medtronic
• MicroPort
• NIHON KOHDEN
• OSYPKA MEDICAL
• Pacetronix
• Philips
• SCHILLER
• Stryker
• vitatron
  
   
• Abbott is renowned for its cutting-edge medical devices and diagnostics, particularly in cardiovascular care, diabetes management, and neuromodulation. Their commitment to innovation and patient-centric solutions ensures high-quality, reliable products that improve patient outcomes. Abbott's strong focus on research and development, combined with their extensive global reach, makes them a trusted partner in the healthcare industry.
   
• Medtronic is a global leader in medical technology, offering a wide range of products and therapies for various medical conditions, including cardiac and vascular diseases, diabetes, and neurological disorders. Their dedication to advancing medical technology and improving patient care is evident in their innovative solutions and robust product portfolio. Medtronic's emphasis on quality, reliability, and patient safety has established them as a trusted partner for healthcare professionals worldwide.
   

Cardiac Rhythm Management Devices Industry News:

• In July 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR dual chamber (DR) leadless pacemaker system. This product launch helped the company increase its customer base.
   
• In May 2023, Medtronic plc announced U.S. Food and Drug Administration (FDA) approval of its Micra AV2 and Micra VR2, the next generation of its industry-leading miniaturized, leadless pacemaker. This product approval helped the company  enhance its cardiac rhythm management devices product portfolio and generate increased business revenue.
   

The cardiac rhythm management devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Pacemakers
  • Implantable pacemakers
  • External pacemakers
• Defibrillators
  • Implantable cardioverter defibrillator (ICDs)
    • Subcutaneous implantable cardioverter defibrillator
    • Transvenous implantable cardioverter defibrillator
      • Single-chamber ICDs
      • Dual-chamber ICDs
  • External defibrillator
    • Manual external defibrillator
    • Automated external defibrillator
      • Semi-automated external defibrillator
      • Fully automated external defibrillator
    • Wearable cardioverter defibrillator
• Cardiac resynchronization therapy devices
  • Cardiac resynchronization therapy devices- D
  • Cardiac resynchronization therapy devices- P

Market, By Application

• Congestive heart failure
• Arrhythmias
• Bradycardia
• Tachycardia
• Other applications

Market, By End Use

• Hospitals
• Cardiac care centers
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE